glaucoma/headache

FIELD OF THE INVENTION The invention provides cyclohexylamine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists, pharmacological compositions comprising the derivatives, and methods of treating diseases and disorders responsive to antagonism of NMDA receptors using the derivatives. BACKGROUND

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs, as well as novel intermediates of the 4-substituted analogs. The analogs are selectively active as antagonists of

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 2-substituted piperidine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also directed to the use of 2-substituted piperidine analogs as

BACKGROUND OF THE INVENTION 1. Field of the Invention This invention is related to 4-substituted piperidine analogs, including hydroxypiperidine and tetrahydropyridine analogs. The analogs are selectively active as antagonists of N-methyl-D-aspartate (NMDA) receptor subtypes. The invention is also

FIELD OF INVENTION The invention relates to piperidine derivatives as N-Methyl-D-Aspartate (NMDA) antagonists useful in the treatment of diseases and disorders responsive to antagonism of NMDA receptors. BACKGROUND OF THE INVENTION Many of the physiological and pathophysiological effects of the

CROSS REFERENCE TO RELATED APPLICATIONS This application is a 371 of International Application No. PCT/EP2010/057598 filed Jun. 1, 2010. The invention relates to 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-- 2-ylamino)phenyl]-benzamide (also known as "imatinib"

BACKGROUND Manoalide is a compound isolated from a marine sponge [E. D. de Silva et al., Tetrahedron Letters 21:1611-1614 (1980)] which has anti-inflammatory, immunosuppressive and analgesic properties. Manoalide the structure of which is shown below, includes a 5-hydroxy-2(5H)-furanone moiety,

PRIORITY The present application claims the benefit of Indian Provisional Patent Application No. 1840/CHE/2012 filed on 10 May 2012 and the International Application No. PCT/IB2013/050924 filed on 4 Feb. 2013, the entire disclosure of which is relied on for all purposes and is incorporated into this

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

BACKGROUND OF THE INVENTION Mammalian Endogenous Cannabinoid System The various elements of the mammalian endogenous cannabinoid system (ECS) constitute a variety of pharmacological targets for the broad group of compounds generally termed as cannabinoids. Included among these elements are two types

The present invention relates to triazine compounds and cyclic diazo analogs thereof having sodium channel blocking properties, and to use of the compounds for preparation of medicaments for treatment of associated disorders. U.S. Pat. No. 4,649,139 discloses compounds of the formula

CROSS-REFERENCE TO RELATED APPLICATIONS This application is the National Stage of International Application No. PCT/GB2009/050033, filed on Jan. 16, 2009, which claims the priority date of United Kingdom Application No. 0800741.1, filed on Jan. 16, 2008 the contents of both being hereby incorporated